

BOB ICB Board Meeting in Public

Responses to the public questions submitted to the 19 March 2024 Board meeting:

Ref	Questions / Comments
<p>No. 1 (Item 10)</p>	<p>Item 10 paper summarises feedback to date on the Primary Care Strategy consultation. The paper does not yet capture the views formally submitted by the representative body of General Practice (LMCs) and there is therefore the possibility that the Board will not have adequate sight of the concerns of the profession. These include, but are not limited to, a lack of acknowledgement of practice non-viability and sustainability challenges, the need to prioritise interface reform; the impact of hub working on continuity of care, the GP identity, and patient inequalities; the impact of preventative care on workforce and contracts; metrics that assess general practice rather than the whole of primary care and the rest of the ICS; and the absence of a building on current GP leadership structures. We understand the paper was written before all feedback was complete. As this feedback presents challenges to the fundamentals of the PCS, will the board have a formal opportunity to review the full feedback in a future paper which directly captures these concerns before proceeding onto next steps?</p> <p><i>Questions submitted by Dr. Richard Wood, CEO – Berkshire, Buckinghamshire & Oxfordshire LMC</i></p>
<p>Response</p>	<p>The purpose of this paper is to provide an update to the Board on the development of the Primary Care Strategy. At this stage we are giving an indication of some of the main themes emerging from our engagement but not all the detail. We are still engaging with partners and the event taking place on 20 March gives us time to discuss what we have heard with a wider group of stakeholders.</p> <p>The Strategy will be presented to the Board for approval in May. Prior to this an Engagement report and responses from partners will be shared with all Board members. In addition, the Board will have time to discuss this at a workshop session in April. When the Strategy is presented for approval, we will outline what we heard during engagement and how this has been taken into account.</p>
<p>No. 2 (Not related to agenda item)</p>	<p>As the new Community Diagnostic Centre review now includes Fibroscan to be an additional diagnostic test that can be performed in a CDC, do you have plans to include Fibroscan for early detection of liver disease and cancer into your CDCs? If yes may I ask when and who I can contact to discuss further.</p> <p><i>Question submitted by Suzanne Walker, Community Liver Health Diagnostic Lead, Echosens</i></p>
<p>Response</p>	<p>Oxford CDC are planning to offer Fibroscan in 2024/25. None of the other CDCs in our geography are currently planning to introduce this test.</p>